Protocols: Booming Moderna adds staff, new clinical program; Lilly boasts of R&D gains
As promised, fast-growing Moderna has moved its second program into clinical development. The mRNA specialist now has mRNA 1440 and mRNA 1851, infectious disease vaccine candidates, in early stage studies. And there are eight more headed to the clinic later in the year. The busy clinical agenda at Moderna comes as the company reports a cash cache of 1B and the recent addition of 120 staffers, boosting the total to 440.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.